119 related articles for article (PubMed ID: 31486887)
21. Dermatomyositis and peritoneal papillary serous carcinoma.
Piura B; Meirovitz M; Cohen Y; Horowitz J
Eur J Obstet Gynecol Reprod Biol; 1999 Jan; 82(1):93-6. PubMed ID: 10192494
[TBL] [Abstract][Full Text] [Related]
22. Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study.
Shibutani T; Nagao S; Suzuki K; Kaneda M; Yamamoto K; Jimi T; Yano H; Kitai M; Shiozaki T; Matsuoka K; Sudo T; Yamaguchi S
Int J Clin Oncol; 2020 Mar; 25(3):502-507. PubMed ID: 31677021
[TBL] [Abstract][Full Text] [Related]
23. Treatment and prognostic factors in primary peritoneal carcinoma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
Unal OU; Oztop I; Yazici O; Ozatli T; Inal A; Günaydın Y; Alici S; Demirci U; Cinkir HY; Aktas B; Aslan K; Uncu D; Yilmaz AU; Oksuzoglu B; Buyukberber S
Oncol Res Treat; 2014; 37(6):332-8. PubMed ID: 24903764
[TBL] [Abstract][Full Text] [Related]
24. [Peritoneal papillary serous carcinoma in a patient with previous surgery for breast cancer: clinical case].
Amanti C; Lombardi A; Moscaroli A; Catracchia V; Lo Russo M; Marino G; Conte S; Provenza G
G Chir; 2006; 27(1-2):45-8. PubMed ID: 16608633
[TBL] [Abstract][Full Text] [Related]
25. Poor Prognostic Factors in Patients Undergoing Surgery After Neoadjuvant Chemotherapy for Ovarian, Tubal, or Peritoneal Cancer.
Kaban A; Topuz S; Saip P; Sozen H; Celebi K; Salihoglu Y
J Obstet Gynaecol Can; 2017 Dec; 39(12):1163-1170. PubMed ID: 28784563
[TBL] [Abstract][Full Text] [Related]
26. Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
Cheng M; Lee HH; Chang WH; Lee NR; Huang HY; Chen YJ; Horng HC; Lee WL; Wang PH
Int J Environ Res Public Health; 2019 Nov; 16(23):. PubMed ID: 31795359
[TBL] [Abstract][Full Text] [Related]
27. Psammomacarcinoma of the peritoneum.
Piura B; Rabinovich A; Yanai-Inbar I
Eur J Obstet Gynecol Reprod Biol; 2001 Aug; 97(2):231-4. PubMed ID: 11451554
[TBL] [Abstract][Full Text] [Related]
28. A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma.
Brown JV; Micha JP; Rettenmaier MA; Abaid LN; Lopez KL; Goldstein BH
Int J Gynecol Cancer; 2010 Oct; 20(7):1132-6. PubMed ID: 21495214
[TBL] [Abstract][Full Text] [Related]
29. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
Park J; Eoh KJ; Nam EJ; Kim S; Kim SW; Kim YT; Lee JY
Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of primary extraovarian peritoneal serous papillary carcinoma with stage III-IV ovarian papillary serous carcinoma].
Gao YN; Liu JX; Wang W; Li WF; Tang WS
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):171-3. PubMed ID: 15946570
[TBL] [Abstract][Full Text] [Related]
31. Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in primary epithelial ovarian cancer.
Muallem MZ; Sehouli J; Richter R; Babayeva A; Gasimli K; Parashkevova A
Int J Gynecol Cancer; 2020 Jan; 30(1):62-66. PubMed ID: 31744887
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal/ovarian cancer patients.
Kusunoki S; Terao Y; Hirayama T; Fujino K; Ujihira T; Ota T; Takeda S
Taiwan J Obstet Gynecol; 2018 Oct; 57(5):650-653. PubMed ID: 30342644
[TBL] [Abstract][Full Text] [Related]
33. [A case of primary peritoneal carcinoma successfully treated using Paclitaxel and Carboplatin chemotherapy].
Takagi K; Tamura A; Hayasaka J; Watanabe A; Okamoto E; Kusano-Kitazume A; Kondo M; Shibayama T; Suenobu Y; Ohtaka Y; Akita H; Tei S
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2490-2. PubMed ID: 25731567
[TBL] [Abstract][Full Text] [Related]
34. Peritoneal papillary serous carcinoma: response to Taxol in platinum resistant disease.
Wilailak S; Kudelka AP; Donner LR; Silva E; Mante R; Kavanagh JJ
Eur J Gynaecol Oncol; 1995; 16(3):187-9. PubMed ID: 7664764
[TBL] [Abstract][Full Text] [Related]
35. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
36. Lymph node spread in stage III or IV primary peritoneal serous papillary carcinoma.
Dubernard G; Morice P; Rey A; Camatte S; Pautier P; Lhommé C; Duvillard P; Castaigne D
Gynecol Oncol; 2005 Apr; 97(1):136-41. PubMed ID: 15790449
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Duska LR; Java JJ; Cohn DE; Burger RA
Gynecol Oncol; 2015 Nov; 139(2):221-7. PubMed ID: 26335594
[TBL] [Abstract][Full Text] [Related]
38. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
[TBL] [Abstract][Full Text] [Related]
39. Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy.
Ransom DT; Patel SR; Keeney GL; Malkasian GD; Edmonson JH
Cancer; 1990 Sep; 66(6):1091-4. PubMed ID: 2400962
[TBL] [Abstract][Full Text] [Related]
40. Weekly topotecan in a heavily pretreated patient with peritoneal papillary serous adenocarcinoma.
Evans J
Int J Gynecol Cancer; 2004; 14(3):540-2. PubMed ID: 15228430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
